Epidural Electrical Stimulation for Stroke Rehabilitation: Results of the Prospective, Multicenter, Randomized, Single-Blinded Everest Trial. by Levy, Robert M et al.
UC Irvine
UC Irvine Previously Published Works
Title
Epidural Electrical Stimulation for Stroke Rehabilitation: Results of the Prospective, 
Multicenter, Randomized, Single-Blinded Everest Trial.
Permalink
https://escholarship.org/uc/item/38h3v0s4
Journal
Neurorehabilitation and neural repair, 30(2)
ISSN
1545-9683
Authors
Levy, Robert M
Harvey, Richard L
Kissela, Brett M
et al.
Publication Date
2016-02-01
DOI
10.1177/1545968315575613
License
CC BY 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Neurorehabilitation and
Neural Repair
2016, Vol. 30(2) 107 –119
© The Author(s) 2015
Reprints and permissions: 
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1545968315575613
nnr.sagepub.com
Clinical Research Article
Introduction
Hemiparesis is the most common cause for functional motor 
limitations poststroke. Approximately 6 months poststroke, 
30% to 66% of stroke patients regain partial functional 
upper limb use,1-4 and less than 20% completely recover.2,5 
Upper limb motor training is an essential part of a compre-
hensive poststroke rehabilitation program, but the benefits 
of training vary among patients. Recent evidence indicates 
that task-oriented therapies targeting arm and hand function 
are effective in specific subsets of patients,6 but a majority 
575613 NNRXXX10.1177/1545968315575613Neurorehabilitation and Neural RepairLevy et al
research-article2015
1Marcus Neuroscience Institute, Boca Raton, FL, USA
2Northwestern University Feinberg School of Medicine, Chicago, IL, USA
3The Rehabilitation Institute of Chicago, Chicago, IL, USA
4University of Cincinnati, Cincinnati, OH, USA
5University of Southern California, Los Angeles, CA, USA
6Oregon Health & Science University, Portland, OR, USA
7University of California, Irvine, CA, USA
8St. Jude Medical, Plano, TX, USA
Corresponding Author:
Richard L. Harvey, The Rehabilitation Institute of Chicago, 345 East 
Superior Street, Chicago, IL 60611, USA. 
Email: rharvey@ric.org
Epidural Electrical Stimulation for Stroke 
Rehabilitation: Results of the Prospective, 
Multicenter, Randomized, Single-Blinded 
Everest Trial
Robert M. Levy, MD, PhD1, Richard L. Harvey, MD2,3, Brett M. Kissela, MD4, 
Carolee J. Winstein, PhD5, Helmi L. Lutsep, MD6, Todd B. Parrish, PhD2,  
Steven C. Cramer, MD7, and Lalit Venkatesan, PhD8
Abstract
Background. This prospective, single-blinded, multicenter study assessed the safety and efficacy of electrical epidural motor 
cortex stimulation (EECS) in improving upper limb motor function of ischemic stroke patients with moderate to moderately 
severe hemiparesis. Methods. Patients ≥4 months poststroke were randomized 2:1 to an investigational (n = 104) or control 
(n = 60) group, respectively. Investigational patients were implanted (n = 94) with an epidural 6-contact lead perpendicular to 
the primary motor cortex and a pulse generator. Both groups underwent 6 weeks of rehabilitation, but EECS was delivered to 
investigational patients during rehabilitation. The primary efficacy endpoint (PE) was defined as attaining a minimum improvement 
of 4.5 points in the upper extremity Fugl-Meyer (UEFM) scale as well as 0.21 points in the Arm Motor Ability Test (AMAT) 4 
weeks postrehabilitation. Follow-up assessments were performed 1, 4, 12, and 24 weeks postrehabilitation. Safety was evaluated 
by monitoring adverse events (AEs) that occurred between enrollment and the end of rehabilitation. Results. Primary intent-
to-treat analysis showed no group differences at 4 weeks, with PE being met by 32% and 29% of investigational and control 
patients, respectively (P = .36). Repeated-measures secondary analyses revealed no significant treatment group differences in 
mean UEFM or AMAT scores. However, post hoc comparisons showed that a greater proportion of investigational (39%) 
than control (15%) patients maintained or achieved PE (P = .003) at 24 weeks postrehabilitation. Investigational group mean 
AMAT scores also improved significantly (P < .05) when compared to the control group at 24 weeks postrehabilitation. 
Post hoc analyses also showed that 69% (n = 9/13) of the investigational patients who elicited movement thresholds during 
stimulation testing met PE at 4 weeks, and mean UEFM and AMAT scores was also significantly higher (P < .05) in this subgroup 
at the 4-, 12-, and 24-week assessments when compared to the control group. Headache (19%), pain (13%), swelling (7%), 
and infection (7%) were the most commonly observed implant procedure-related AEs. Overall, there were 11 serious AEs 
in 9 investigational group patients (7 procedure related, 4 anesthesia related). Conclusions. The primary analysis pertaining to 
efficacy of EECS during upper limb motor rehabilitation in chronic stroke patients was negative at 4 weeks postrehabilitation. 
A better treatment response was observed in a subset of patients eliciting stimulation induced upper limb movements during 
motor threshold assessments performed prior to each rehabilitation session. Post hoc comparisons indicated treatment effect 
differences at 24 weeks, with the control group showing significant decline in the combined primary outcome measure relative 
to the investigational group. These results have the potential to inform future chronic stroke rehabilitation trial design.
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of patients do not regain adequate motor function with reha-
bilitation alone.7,8
Neuronal plasticity in surviving motor and premotor cor-
tices is presumed to play a major role in motor recovery 
poststroke.9-12 Evidence suggests that plasticity can be mod-
ulated by various exogenous means: behavioral training, 
plasticity-enhancing drugs, and electrical stimulation.13 
Results from preclinical studies using cortical stimulation 
(CS) in experimental animal models with motor deficits 
induced by focal cortical lesions illustrate the importance of 
pairing CS with skilled motor training for providing behav-
ioral and neurophysiological benefits.14-16
Evidence obtained from noninvasive CS studies using 
repetitive transcranial magnetic stimulation (rTMS)17-20 and 
transcranial direct current stimulation (tDCS)21,22 substanti-
ate claims for the role of CS in improving motor skill in the 
hemiparetic hand. Both these noninvasive techniques have 
practical limitations for use in a clinical setting. The cranial 
anatomical target for TMS or tDCS must be reestablished at 
each therapeutic session,23 and TMS cannot be applied dur-
ing motor training. In contrast, invasive electrical CS 
involves epidural or subdural placement of the stimulating 
electrode at the target, allowing for greater consistency and 
ease in delivering stimulation throughout the course of task-
oriented motor training. TMS and tDCS are relatively safe, 
but extent of the induced electrical field on the cortical sur-
face is highly dependent on the positioning of the coil or 
electrode delivering stimulation. Predictive modeling stud-
ies have shown that direct electrical CS has the spatial reso-
lution of a few millimeters, whereas the TMS resolution 
spans several centimeters.24 The depth of penetration of 
conventional TMS coils is approximately 2 cm from the 
scalp and there is a tradeoff between spatial resolution and 
depth of penetration of the induced field.25 Computational 
modeling using an extruded slab of cortical neurons indi-
cates that electrical CS can stimulate neurons deep within 
the sulci at higher thresholds when compared to the neurons 
on the crowns or lips of the gyri.26 But, our knowledge of 
differences in efficacy between the 2 stimulation techniques 
is limited as there are no human clinical studies directly 
comparing the effectiveness and sustainability of these 
neurostimulation modalities.
Two multicenter clinical feasibility studies27,28 examined 
the effectiveness of epidural electrical CS (EECS) delivered 
during rehabilitation in stroke patients with upper limb 
hemiparesis. Significant improvements in upper limb motor 
function were observed in the investigational groups com-
pared to their respective control groups.
In this study, we evaluated the safety and efficacy of a 
larger, prospective, multicenter, single-blinded, randomized 
phase-III clinical trial called Everest. We hypothesized that 
the combination of EECS and task-oriented upper limb motor 
rehabilitation would result in a greater proportion of patients 
achieving clinically meaningful improvements in motor con-
trol, and arm and hand motor function when compared to 
patients undergoing only rehabilitation. This study also 
assessed the safety of an EECS system in treating motor 
deficits in patients with chronic stroke.
Methods
Study Design
This prospective, randomized, single-blind, multicenter 
study was conducted at 21 sites in the United States, and 
was approved by the institutional review board at each 
study site. The trial was conducted under an Investigational 
Device Exemption from the Food and Drug Administration 
(FDA). All study participants provided written informed 
consent prior to entering the study.
The primary objectives of the study were to determine 
the safety and efficacy of targeted subthreshold EECS 
delivered during task-oriented rehabilitation in order to 
enhance motor recovery in chronic stroke patients with 
upper limb hemiparesis. A detailed description of the study 
design, patient selection criteria, and methods were previ-
ously published.29 We briefly review the design in the sec-
tions below.
Study Participants
Inclusion criteria: Male and female subjects at least 21 
years old with moderate to moderately severe upper 
extremity hemiparesis due to an ischemic infarct that 
occurred ≥4 months prior to enrollment were considered 
for this study. Moderate to moderately severe impair-
ment was defined as a score of 28 to 50 (inclusive) on the 
upper extremity Fugl-Meyer scale (UEFM).30-35
Exclusion criteria: Subjects with a primary hemorrhagic 
stroke, severe sensory deficit, or moderate to severe 
hemispatial neglect and/or anosognosia; or a history of 
seizures were excluded from this study.
After screening, patients underwent baseline evaluations 
and assessments of UEFM, Arm Motor Ability Test (AMAT) 
scores,36 the Box and Block Test, structural and functional 
magnetic resonance imaging (MRI and fMRI), Stroke-
Specific Quality of Life Scale (SS-QOL), and a neuropsy-
chological testing battery. The neuropsychological 
assessments have been described in detail previously.29 In 
this article, we evaluate the 4-, 12-, and 24-week assess-
ments of the composite primary efficacy endpoint (ie, 
UEFM and AMAT scores).
Randomization
Subjects were randomized in a 2 to 1 ratio to an investiga-
tional or control group, respectively. Computer-generated 
randomization was performed at a central location by using 
a site-specific block design with random block sizes of 3, 6, 
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or 9. Investigational group patients were implanted with the 
EECS system and then received 6 weeks of task-oriented 
upper limb motor rehabilitation with EECS turned on only 
during the rehabilitation sessions. Patients in the control 
group were not implanted; nor did they undergo sham sur-
gery. To parallel the timing of rehabilitation in the investi-
gational group, rehabilitation for control group patients was 
initiated 2 to 4 weeks after randomization, and also lasted 
for 6 weeks. Both the investigational and control groups 
were followed up for 24 weeks after completing the reha-
bilitation program, with assessment visits occurring at 
weeks 1, 4, 12, and 24 (Figure 1).
Blinding
Patients and the clinicians involved in patient care were not 
blinded, but assessors of outcome measures were blinded to 
treatment group assignment. To maintain assessor blinding, 
all patients, regardless of group assignment, masked any 
evidence of the neurosurgical procedure by wearing a cloth 
hood during testing.
Imaging
The imaging protocol was previously described.29 Briefly, 
structural MRI was used to verify the anatomical location of 
the stroke, and fMRI was used to identify the cortical target 
area associated with defined active wrist and hand move-
ments in the affected limb. The fMRI task was a simple 
block design in which the participant elevated their affected 
wrist approximately 5° and returned to the neutral position 
every 2 seconds during the 30-second active block. 
Participants were instructed to remain still during the 
30-second control block. The forearm and wrist were fixed 
in a plastic holder, and 2 runs of 4 minutes and 30 seconds 
were collected of the same movement. Data were concate-
nated if both sessions lacked any movement contamination; 
else a single uncorrupted run was used to identify the acti-
vation. Analysis was conducted in SPM5 after motion cor-
rection, slice timing correction, and spatial smoothing (2 
times the voxel dimension). Functional data were coregis-
tered to the participant’s 3-dimensional anatomical T1 vol-
ume to facilitate the surgical placement. The contrast used 
to generate the functional activation map was active (wrist 
movement) greater than control (rest). Selection of the stim-
ulation site was limited to the ipsilesional hemisphere and 
had to be located in (or near) known motor-sensory regions 
to avoid any artifactual activation. Because of the robust 
nature of the motor response even in this population, the 
activation was typically along the intact motor cortex just 
anterior to the central sulcus. The center of mass of the acti-
vation cluster was identified by coordinates that were trans-
ferred to the structural scan. The structural scan was then 
labeled at the coordinate to be used as a target for the surgi-
cal placement of the electrode.
Cortical Stimulation System
The EECS system consisted of an implantable pulse gener-
ator (IPG), the lead, and a handheld stimulation program-
mer.29 Stimulation frequency, pulse width, and stimulation 
amplitude could be programmed in 5 Hz (range = 5-150 
Hz), 25 µs (range = 25-300 µs), and 0.25 mA (range = 0-13 
mA) increments, respectively. The EECS lead used a 6-ele-
ment platinum-iridium electrode grid configured in a flexi-
ble 2 by 3 element array encased in a silicone sheath. The 
electrode contacts were 3 mm in diameter and spaced 9 mm 
[center-to-center] apart, making the effective stimulation 
area of the electrode ~1.8 cm2.28
Implantation Procedure
The patient was under general anesthesia during the implant 
procedure. An extradural craniotomy (~4 cm in diameter) 
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Figure 1. Clinical trial design.
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was performed above the predetermined cortical area. The 
stimulation electrode was placed on the dura mater over the 
target location, as predetermined using frameless stereo-
taxic neuronavigation, and was anchored with dural sutures. 
The lead was then tunneled beneath the scalp and the skin 
of the neck and exited at the subclavicular pocket for con-
nection to the IPG.
Cortical Stimulation Programming
Three electrode contacts along one edge of the lead were 
configured as anodes, and 3 contacts on the opposite edge 
were programmed as cathodes. Prior to initiation of the 
6-week rehabilitation intervention, the stimulator output 
current level was programmed based on movement thresh-
old (MT) testing. The IPG output current level was adjusted 
in 1-mA increments up to 13 mA at 50 Hz and 250 µs to 
determine the minimum current level required to elicit vis-
ible or palpable hand or arm muscle response (ie, MT). The 
stimulation amplitude used during rehabilitation therapy 
was 50% of the MT. The choice of 50% of MT was based 
on preclinical data in rat stroke models suggesting that sub-
threshold (50% of MT) stimulation was superior to supra-
threshold stimulation in achieving improved motor skill and 
dendritic volume during EECS with motor training.14 If no 
muscle response could be induced during testing, the stimu-
lator was set at 6.5 mA, which is 50% of maximum pulse 
generator output. These stimulation parameters were 
unchanged throughout the rehabilitation intervention. 
EECS was initiated approximately 5 minutes prior to the 
start of each rehabilitation session, and was discontinued at 
the end of each session.
Rehabilitation Protocol
Both investigational and control groups participated in a 
6-week rehabilitation program29,37 that consisted of approx-
imately 2.5 hours of therapy per day (2 sessions per day, 
60-75 minutes per session). Rehabilitation was conducted 5 
days a week for the first 4 weeks and 3 days a week for the 
next 2 weeks (total = 26 days or 65 treatment hours). The 
first session each day focused on motor activities and move-
ments appropriate for the patient (ie, improvements in coor-
dination and the abilities to grasp, release, and reach). After 
a rest break, the subsequent session focused on activities of 
daily living and self-selected functional activities using the 
affected arm and hand. Functional activities were selected 
using the Canadian Occupational Performance Measure 
(COPM) performed at baseline.38,39 During this assessment, 
the patient selected 5 motor tasks that were most challeng-
ing to perform independently. Two of these were selected as 
focused goals for therapy and the therapist also encouraged 
the subject to work on these tasks at home during the 6-week 
rehabilitation period. The EECS system was explanted 
approximately 8 weeks after completion of the rehabilita-
tion protocol (Figure 1). On completion of the rehabilitation 
protocol, investigators instructed patients not to participate 
in additional physical/occupational therapy (except speech 
therapy) during the rehabilitation program and the first 4 
weeks of follow-up.
Study Outcomes
Two primary outcome measures were used in this study: the 
UEFM and the AMAT. UEFM is a standardized quantitative 
assessment of neurological and motor impairment. AMAT 
is both a qualitative and quantitative assessment of upper 
limb function in activities of daily living. Raters were 
trained and their rating skill was tested prior to data collec-
tion, and retested every 6 months throughout the course of 
the study. The primary outcome measure was defined as the 
percentage of patients with clinically meaningful improve-
ments in both the UEFM and AMAT measures when 
assessed 4 weeks postrehabilitation. A clinically meaning-
ful improvement was defined a priori as a 4.5-point 
improvement from baseline in the UEFM (out of a total of 
66 points) and a 0.21-point improvement in the AMAT 
function (out of a total of 5 points). The target criterion for 
the UEFM and AMAT scales were chosen on the basis of 
pooled results from prior rehabilitation studies in patients 
with chronic hemiparesis.27,28,40
Secondary outcome measures included (a) absolute 
change from baseline in UEFM and AMAT scores, mea-
sured at weeks 4, 12, and 24 postrehabilitation and (b) clini-
cally meaningful improvement in UEFM and AMAT at 
weeks 12 and 24.
Statistical Analysis
The statistical analysis plan was previously described in 
detail.29 Briefly, the efficacy of the intervention was tested 
using intent to treat analysis comparing the proportion of 
patients in the investigational group achieving success with 
those in the control group. Missing data were imputed by 
carrying forward the data from the previous assessment. A 
z-score was calculated based on the difference of these pro-
portions and tested for significance using a 1-sided test (α = 
.025). To examine differences in the proportions of subjects 
in each treatment group who achieve clinical success across 
time, covariate adjusted analyses of the primary efficacy 
endpoint were conducted using logistic regression. 
Covariates included baseline UEFM, time since stroke, 
handedness, age, gender, and investigational site. Secondary 
analyses compared mean changes in UEFM and AMAT 
scores between investigational and control groups at 4, 12, 
and 24 weeks posttreatment using repeated-measures mod-
els. These comparisons accommodated the nonindepen-
dence of observations from subjects and allowed for the 
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comparison of outcomes between treatment groups during 
the study period and at specific time points (repeated-mea-
sures analysis of variance). Follow-up post hoc compari-
sons between treatment groups at any given time point were 
done using a 1-sample t test. For all secondary analyses, 
P ≤ .05 was considered statistically significant.
Safety Assessments
Details of the description and classification of adverse 
events (AEs) and serious adverse events (SAEs) have been 
previously published.29 In brief, a data and safety monitor-
ing board was responsible for reviewing safety data. Safety 
assessments included the monitoring of adverse events, 
concomitant medications, postoperative clinical and neuro-
logical examinations, and stimulation system checks. 
Investigators judged whether each AE was related to the 
underlying disease state, to the device, or to the study pro-
cedure, and this assessment was documented on the case 
report form. The AEs that were categorized prior to study 
enrollment were characterized as anticipated events, and 
any other event recorded was classified as an unanticipated 
event.
Results
A total of 373 patients consented to participate in the Everest 
study. A total of 164 patients who met the study’s inclusion/
exclusion criteria were randomized into 104 investigational 
and 60 control subjects. Of the 104 who were randomized to 
the investigational group, 94 received a cortical implant 
(prior to device implantation, 9 subjects declined to con-
tinue in the study and 1 subject experienced a second 
stroke). Out of the 60 subjects randomized to the control 
group, 58 received the rehabilitation therapy (prior to enter-
ing therapy, 2 subjects declined to continue in the study). 
Each patient completed the study within approximately 8 
months, which included 1 to 2 weeks of baseline activities, 
6 weeks of treatment, and 24 weeks of follow-up (Figure 1). 
All 6-weeks of rehabilitation was completed by 97% of the 
investigational (91/94) and control group (56/58) patients. 
Because of study attrition, 91, 89, and 87 investigational 
and 55, 54, and 52 control group patients completed the 4-, 
12-, and 24-week assessments, respectively.
Handedness, time since stroke, and National Institutes of 
Health Stroke Scale score differed between investigational 
and control groups at baseline (Table 1), with investiga-
tional group patients having greater stroke severity and lon-
ger time since stroke (P < .05). The dominant hand was 
more often hemiparetic in the investigational group (P < .05). 
We separated the investigational group into those who 
achieved MT during programing (MT) and those who did 
not (non-MT). The investigational MT subgroup had sig-
nificantly smaller lesion volumes (P < .01), and the stroke 
location was primarily isolated to the basal ganglia and/
internal capsule in a majority of the patients (Table 1) when 
compared with the non-MT subgroup and the control group. 
None of the other patient characteristics were significantly 
different between the investigational and control groups.
Primary Outcome Measure
There was not a significant difference between the investi-
gational and control group for the primary outcome mea-
sure, as a clinically meaningful improvement was observed 
in 32% (95% CI 22% to 41%) of investigational, and 29% 
(95% CI 17% to 41%) of control group patients at 4 weeks 
postrehabilitation (P = .36). After adjusting for differences 
in baseline UEFM, time since stroke, handedness, age, and 
gender, results remained nonsignificant between treatment 
groups at the 4-week follow-up.
Secondary analyses using repeated-measures models 
that accommodate the nonindependence of observations 
revealed no significant difference between the investiga-
tional and control groups in the proportion of patients reach-
ing the composite primary endpoint at the 12 week 
assessment. However, at 24 weeks postrehabilitation, a sig-
nificantly higher number (post hoc comparison, P = .003) of 
investigational group patients (39%) attained or maintained 
the primary efficacy endpoint compared to the control 
group (15%; Figure 2, Tables 2 and 3).
Other Secondary Outcome Measures
Repeated-measures secondary analyses revealed no signifi-
cant treatment group differences in mean UEFM or AMAT 
scores over time. The average AMAT improvement for 
investigational group subjects showed a trend toward sig-
nificantly greater change from baseline than control group 
subjects at week 4 (P = .06). The improvement was gener-
ally sustained for both groups throughout the 12-week fol-
low-up, but the investigational group subjects maintained 
their performance on the primary outcome to a greater 
degree (P = .003) at follow-up week 24 than the control 
group (Figure 2A). This was especially notable for AMAT 
scores measured at 24 weeks (Table 2), which were signifi-
cantly different between the investigational and control 
groups (post hoc comparison, P < .05).
Post Hoc Subset Analysis
Movements were elicited during MT testing (performed 
prior to the rehabilitation sessions) in 13 of the 91 (14%) 
investigational group patients at the 4-week follow-up. A 
subgroup analysis was conducted to determine whether the 
MT subgroup achieved significant primary target endpoint 
outcomes compared with the control group. At 4 weeks 
postrehabilitation, a significant number (P = .002) of the 
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MT subgroup patients (69%; 95% CI 44% to 94%) achieved 
clinically meaningful improvement when compared to the 
control group (29%; 95% CI 17% to 41%). Mean changes 
in UEFM and AMAT scores also suggest treatment group 
differences over the 24-week follow-up period. Interestingly, 
a greater proportion of patients in both the investigational 
MT and investigational non-MT groups (P = .005) achieved 
clinical success at week 24 compared with the control group 
(Figure 2B). A post hoc white matter tract analysis41 on a 
subset (n = 60) of the 94 investigational group patients 
showed that the amount of corticospinal tract damage in the 
MT subgroup was lower than the investigational non-MT 
subgroup. Investigational group patients who achieved the 
primary efficacy endpoint had a smaller degree of cortico-
spinal tract damage when compared with the control 
group.41
Safety
Adverse events that occurred during each study phase (pre-
treatment, implant, rehabilitation, explant, and follow-up) 
are shown in Table 4. Overall, 244 AEs in 77 patients and 
40 SAEs in 25 patients occurred in the investigational group 
and 43 AEs in 21 patients and 6 SAEs in 6 patients occurred 
in the control group. From the investigational group, 111 
(45%) of the AEs and 27 (67%) of the SAEs were unrelated 
to the EECS device or procedure. Of the remaining 133 AEs 
from the investigational group, 4 (3 anticipated) were 
device related and 126 (85 anticipated) were procedure 
related (Tables 5 and 6). The most common procedure-
related AEs observed were headache (n = 26), pain (n = 19), 
swelling (n = 7), and infection (n = 7) at the implant site, 
which occurred in 20, 14, 7, and 7 patients, respectively. 
There were also 8 occurrences of hematoma/bleeding at the 
implant site and 1 hemorrhage (Table 5). A majority of the 
device- and procedure-related AEs resolved without any 
sequelae and not classified as SAEs. One death occurred in 
the investigational group after a large recurrent stroke and 
respiratory failure and was not associated with the study.
Overall, there were 40 SAEs (anticipated SAEs = 11; 
unanticipated SAEs = 29) in 25 investigational group sub-
jects, and the likelihood of a patient in the investigational 
group having any SAE was 24% (95% CI 16% to 33%). A 
majority of these SAEs (77%) occurred either during 
implant (32%) or postrehabilitation (45%). Eleven SAEs 
occurred in 9 subjects that were related to implantation or 
removal of the study device (Tables 5 and 6). Three of these 
events resulted in early surgical removal of the device, due 
to wound infection at device implant site, persistent head-
ache after implant, and bleeding between skull and brain.
Table 1. Subject Demographics and Baseline Measures.
Parameter Investigational (n = 94)
Investigational Non-
MT (n = 81) Investigational MT (n = 13) Control (n = 58)
Female, n (%) 42 (44.7) 36 (44.4) 6 (46.2) 20 (34.5)
Age, years, mean (SD) 56.4 (11.3) 56.6 (11.1) 55.2 (11.7) 57.4 (10.7)
Caucasian, n (%) 83 (88.3) 72 (88.9) 11 (84.6) 52 (89.7)
Neurological disorder other than 
index stroke, n (%)
6 (6.4) 5 (6.1) 1 (7.7) 6 (10.3)
Previous TIA, n (%) 12 (12.8) 9 (11.1) 3 (22.1) 10 (17.2)
Dominant hand affected, n (%) 60 (63.8)a 52 (64.2)a 8 (61.5)a 26 (44.8)
Time since index stroke, months, 
mean (SD)
66.8 (71.0)a 75.6 (79.3)a 44.2 (51.1) 46.2 (47.7)
Prior rehabilitation, n (%) 93 (98.9) 80 (98.8) 13 (100.0) 55 (94.8)
Prior rehabilitation length, days, 
mean (SD)
87.3 (74.4) 86.2 (60.5) 94.4 (59.2) 78.4 (83.6)
Lesion volume, cm3, mean (SD) 23.4 (35.2) 26.3 (26.5) 4.9 (6.32)a 30.4 (42.9)
Location of stroke
 Isolated to basal ganglia and/or 
internal capsule, n (%)
47 (50.0) 36 (44.4) 11 (84.6)a 27 (46.6)
 Involvement of other brain 
structures, n (%)
41 (43.6) 39 (48.1) 2 (15.4)a 29 (50.0)
NIHSS, mean (SD) 2.9 (1.8)a 3.0 (1.5)a 2.6 (1.9) 2.3 (1.34)
UEFM, mean (SD) 37.6 (6.1) 37.4 (7.1) 38.3 (5.0) 37.6 (5.90)
AMAT, mean (SD) 2.97 (0.68) 2.94 (0.5) 3.1 (0.7) 3.02 (0.69)
Abbreviations: MT, movement threshold; TIA, transient ischemic attack; NIHSS, National Institutes of Health Stroke Scale; UEFM, upper extremity 
Fugl-Meyer score; AMAT, Arm Motor Ability Test score.
aSignificant difference (P < .05) when compared with control group.
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Discussion
We report the primary results of the largest clinical trial to 
date on application of epidural cortical stimulation during 
task-oriented motor rehabilitation for recovery of poststroke 
upper extremity hemiparesis. The percentage of patients 
demonstrating predefined, clinically meaningful improve-
ments in both UEFM and AMAT scores at 4 weeks postre-
habilitation was not significantly different between the 
control and investigational groups.
Secondary post hoc analysis revealed a statistically signifi-
cant difference between the proportion of investigational and 
control group patients who attained the combined primary 
endpoint at 24 weeks postrehabilitation. Further post hoc 
analysis of a small subgroup (n = 13) revealed that the MT 
investigational subgroup patients had a 69% success rate in 
achieving the primary endpoint, which is significantly greater 
than the 29% of the control group patients who responded.
This large-scale study also illustrates the safety associ-
ated with an epidural cortical stimulation system implant. 
Figure 2. (A) Comparison of percentage of patients who exhibited the defined clinically meaningful improvement within the 
investigational and control groups. (B) Comparison of percentage of patients who exhibited clinically meaningful improvement 
between the investigational movement threshold (MT) subgroup, investigational non-MT subgroup, and the control group.
*Post hoc comparisons with significance (P < .05) when compared with the control group at the corresponding follow-up visit.
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Safety information collected through the course of the study 
suggests that patients implanted with the EECS system 
were at no greater risk of physical or psychological harm 
than what was previously appreciated at study initiation. 
Although the cortical lead implant procedure was invasive, 
the AEs recorded in this study are common in surgeries 
associated with this modality. The incidence rates of device-
related AEs is substantially lower when compared with 
other neurostimulation modalities such as spinal cord stim-
ulation,42 deep brain stimulation,43,44 and peripheral nerve 
stimulation.45 Frequently occurring device- and procedure-
related AEs in these other stimulation modalities include 
lead migration (13% to 30%), lead breakage (5% to 10%), 
infection (1% to 20%), and pain at the implant site (5% to 
20%). Deep brain stimulation implant procedure–related 
intracranial hemorrhages43 and postimplant seizures44 have 
Table 4. Classification of Adverse Event (AE) Occurrence in 
Control and Investigational Group Subjects as a Result of Each 
Study Phase Starting From Enrollment Through 24 Weeks.a
Study Phase
No. of AEs in 
Investigational 
Group
No. of 
Subjects
No. of AEs 
in Control 
Group
No. of 
Subjects
Device-related 
AEs (including 
SAEs)
N/A N/A
 Pretreatment 0 0  
 Implant 1 1  
 Rehabilitation 4 3  
 Explant 2 2  
 Follow-up 2 2  
 Total 9 7  
Procedure-related 
AEs (including 
SAEs)
N/A N/A
 Pretreatment 0 0  
 Implant 65 38  
 Rehabilitation 19 13  
 Explant 31 25  
 Follow-up 11 10  
 Total 126 57  
SAEs
 Pretreatment 2 1 0 0
 Implant 13 9 N/A N/A
 Rehabilitation 3 3 0 0
 Explant 4 4 N/A N/A
 Follow-up 18 11 6 6
 Total 40 25 6 6
Death
 Pretreatment 0 0 0 0
 Implant 0 0 N/A N/A
 Rehabilitation 0 0 0 0
 Explant 0 0 N/A N/A
 Follow-up 1 (unrelated 
to device/
procedure)
1 0 0
 Total 1 1 0 0
Abbreviations: SAE, serious adverse event; N/A, not applicable.
aThe row corresponding to the total number of subjects will not tally 
with the column corresponding to “No. of Subjects” in instances when 
more than one AE type occurred in the same subject.
Table 2. UEFM and AMAT Scores, and Change From Baseline, 
Over Posttreatment Follow-up Weeks 1, 4, 12, and 24.
Week 1 Week 4 Week 12 Week 24
Investigational 
group, n
91 91 89 87
Control group, n 56 55 54 52
UEFM mean (SD)  
 Investigational 41.0 (8.3) 42.0 (8.5) 42.5 (9.1) 42.3 (9.6)
 Control 40.7 (7.7) 41.2 (7.4) 41.7 (8.5) 41.0 (9.7)
UEFM change mean (SD)
 Investigational 3.5 (5.2) 4.3 (5.3) 4.8 (5.5) 4.6 (6.3)
 Control 3.4 (4.7) 4.0 (4.3) 4.6 (5.4) 3.8 (7.1)
AMAT mean (SD)
 Investigational 3.27 (0.71) 3.36 (0.71) 3.37 (0.76) 3.35 (0.79)a
 Control 3.25 (0.73) 3.27 (0.75) 3.27 (0.76) 3.19 (0.83)
AMAT change mean (SD)
 Investigational 0.28 (0.44) 0.37 (0.47) 0.36 (0.52) 0.35 (0.49)
 Control 0.26 (0.39) 0.26 (0.37) 0.26 (0.45) 0.17 (0.49)
Abbreviations: UEFM, upper extremity Fugl-Meyer score; AMAT, Arm Motor 
Ability Test score.
aPost hoc comparisons with significance (P < .05) when compared with control 
group at the corresponding follow-up visit.
Table 3. Comparison of Changes in UEFM and AMAT 
Scores From Baseline to Weeks 1, 4, 12, and 24 Between 
the Investigational Movement Threshold (MT) Subgroup, 
Investigational Non-MT Subgroup, and the Control Group.
Week 1 Week 4 Week 12 Week 24
Investigational MT 
subgroup, n
13 13 13 13
Investigational non-
MT subgroup, n
78 78 76 74
Control group, n 56 55 54 52
UEFM mean (SD)  
 Investigational MT 
subgroup
5.9 (3.7)a 7.2 (3.3)a 6.5 (3.6)a 6.1 (6.5)a
 Investigational 
non-MT 
subgroup
3.1 (5.3) 3.9 (5.5) 4.5 (5.8) 4.3 (6.2)
 Control 3.4 (4.7) 4.0 (4.3) 4.6 (5.4) 3.8 (7.1)
AMAT change mean (SD)
 Investigational MT 
subgroup
0.49 (0.45)a 0.51 (0.42)a 0.45 (0.49)a 0.46 (0.49)a
 Investigational 
non-MT 
subgroup
0.25 (0.44) 0.35 (0.47) 0.35 (0.52) 0.33 (0.49)a
 Control 0.26 (0.39) 0.26 (0.37) 0.26 (0.45) 0.17 (0.49)
Abbreviations: UEFM, upper extremity Fugl-Meyer score; AMAT, Arm Motor 
Ability Test score.
aPost hoc comparisons with significance (P < .05) when compared with control 
group at the corresponding follow-up visit.
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been reported in 5% and 2% of the patients, respectively. 
Pain at the lead and/or IPG site is common with any neuro-
stimulation device implant procedure and typically subsides 
within 2 to 3 weeks. Superficial infections can be treated 
with antibiotics, but the infections involving hardware 
require device explantation. SAEs such as fever, nausea, 
vomiting, and urinary retention occurred in this study due to 
adverse reactions to the anesthesia procedure associated 
with the device implant. Overall, considering the number of 
patients implanted in this study with the EECS device (n = 
94), and their medical history, the rate of procedure-related 
SAEs was consistent with rates seen with other implanted 
neuromodulation devices used clinically (eg, spinal cord 
stimulators).
The phase I and II trials leading up to the present study 
demonstrated the safety and efficacy of EECS delivered 
during rehabilitation in chronic stroke patients. In the 
Adams trial,27 4 patients with EECS during 3 weeks of reha-
bilitation experienced a sustained 10-point improvement in 
UEFM, compared with a 2-point improvement for the con-
trol group. Likewise, in the Baker trial,28 12 patients with 
Table 5. Characterization of Anticipated Device-, Procedure-, 
and Adverse Drug/Anesthesia-Related Adverse Events (AEs) and 
Serious Adverse Events (SAEs) in Investigational Group Subjects 
From Enrollment Through 24 weeks.a
Anticipated AEs
No. of 
AEs
No. of 
Subjects
Device-related AEs (including SAEs)
 Fracture of electrode, lead, or implantable 
pulse generator
1 1
 Other (tingling sensation) 2 1
 Total 3 2
Procedure-related AEs (including SAEs)
 Bleeding/hematoma at operative site 8 8
 Bleeding between skull and brain 1 1
 Damage to nerve/vasculature in surgical 
area
2 2
 Headache 26 20
 Formation of fibrous tissue/fluid pockets 2 2
 Infection at implant site 7 7
 Neck pain 6 5
 Neural tissue damage 2 1
 Clinically significant pain at operative site 19 14
 Seizure 2 1
 Swelling at operative site 7 7
 Unstable blood pressure 3 2
 Vertigo/dizziness 1 1
 Total 85 46
Adverse drug-/anesthesia-related AEs (including SAEs)
 Fever 2 2
 Hypoxia 0 0
 Nausea 3 3
 Pneumonia 0 0
 Urine retention 2 2
 Vomiting 5 5
 Total 12 11
Procedure-related SAEs
 Bleeding between skull and brain 1 1
 Headache 1 1
 Infection at operative site 2 2
 Clinically significant pain at operative site 1 1
 Seizure 2 1
 Total 7 6
Adverse drug-/anesthesia-related SAEs
 Fever 1 1
 Nausea 1 1
 Urinary retention 1 1
 Vomiting 1 1
 Total 4 4
Other
 Digestive 2 2
 Integument 1 1
 Musculoskeletal 2 2
 Neurologic 7 7
 Renal/urogenital 1 1
 Other body system 2 2
 Total 15 12
aThe row corresponding to the total number of subjects will not tally 
with the column corresponding to “No. of Subjects” in instances when 
more than one AE type occurred in the same subject.
Table 6. Characterization of Unanticipated Device-, 
Procedure-, and Adverse Drug-/Anesthesia-Related 
Adverse Events (AEs) and Serious Adverse Events (SAEs) in 
Investigational Group Subjects.
Unanticipated AEs
No. of 
AEs
No. of 
Subjects
Device-related AEs (including SAEs)
 Other (pain associated with 
implantable pulse generator 
movement)
1 1
 Total 1 1
Procedure-related AEs (including SAEs)
 Cardiovascular 4 4
 Digestive 1 1
 Integument 4 4
 Musculoskeletal 6 6
 Neurologic 4 4
 Pulmonary 2 2
 Renal/urogenital 1 1
 Other body system 7 5
 Total 29 17
Procedure-related SAEs
 Cardiovascular 1 1
 Integument 1 1
 Pulmonary 1 1
 Renal/urogenital 1 1
 Other body system 1 1
 Total 5 4
aThe row corresponding to the total number of subjects will not tally 
with the column corresponding to “No. of Subjects” in instances when 
more than one AE type occurred in the same subject.
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EECS during 6 weeks of rehabilitation experienced a 5.5-
point improvement in UEFM and a 0.4-point improvement 
in AMAT, compared with 1.9- and 0.2-point improvements, 
respectively, for the control group. Observation of greater 
efficacy in these earlier small-scale studies might be 
explained by the greater proportion of patients reaching 
MT, or the lack of blinded trial designs. During study phases 
I and II, MTs were elicited in 75% and 42% of the patients, 
respectively. In this phase III study, only 14% of patients 
exhibited MT during postoperative testing. The inability to 
reach MT calls to question whether the programmed ampli-
tude of subthreshold stimulation during rehabilitation was 
sufficient to induce neuroplasticity.14-16
Inability to achieve MT in this study might alternately be 
explained by suboptimal lead placement. Like prior stud-
ies,27,28 Everest used fMRI to identify the target in the pri-
mary motor cortex innervating the contralateral upper limb. 
However, unlike the Adams study,27 intraoperative cortical 
mapping of evoked motor potentials or gross hand move-
ment was not performed to confirm the target. Furthermore, 
the fMRI hot spot used to locate the target in this study may 
not be indicative of the complete extent of neural damage. 
In the present study, investigational patients in whom a 
motor response could be elicited (MT subgroup) had a 
higher probability of achieving the primary efficacy end-
point when compared with the non-MT investigational and 
the control group.41 The MT subgroup had smaller lesion 
volumes and the stroke location was isolated to the basal 
ganglia and/or internal capsule (Table 1) when compared to 
the non-MT subgroup and the control group. A post hoc 
white matter tract analysis41 on a subset (n = 60) of the 94 
investigational group patients showed that the amount of 
corticospinal tract damage in the MT subgroup was lower 
than in the patients in the investigational non-MT subgroup. 
Furthermore, all investigational group patients who 
achieved the primary efficacy endpoint had a smaller degree 
of corticospinal tract damage.41 But, a recently published 
post hoc imaging analysis46 based on the Everest trial 
patients (both investigational and control group) revealed a 
lack of correlation between lesion volume and motor func-
tion in patients with mild chronic hemiparesis. This study 
showed that the anatomical location of the lesion relative to 
the descending motor pathways was a better predictor of 
arm and hand motor function gains following rehabilitation 
than lesion size alone. Based on these findings, future 
chronic stroke rehabilitation trials should attempt to quan-
tify the anatomical and functional corticospinal tract integ-
rity for patient selection, and to predict treatment outcome. 
Diffusion tensor imaging47,48 and TMS49 have been recently 
used to predict functional motor outcomes in both subacute 
and chronic stroke patients. Additionally, epidural or subdu-
ral CS system implantation procedures should incorporate 
intraoperative motor or somatosensory evoked potential 
mapping to confirm target location during lead placement.
The choice of an appropriate endpoint is vital for studies 
involving new therapeutic modalities. The a priori defini-
tion of clinically meaningful response in the Everest trial 
differed subtly, but notably from the prior safety and feasi-
bility studies using EECS during rehabilitation. In the Baker 
trial,28 a clinically meaningful improvement was defined as 
achieving both 0.21-point AMAT improvement and a 3.5-
point UEFM improvement, which was realized by 50% of 
the patients randomized to stimulation. In Everest, the 
threshold for UEFM in the composite endpoint was 
increased to 4.5 points as per FDA’s recommendation. At 
the time of study initiation, the use of a combined perfor-
mance metric had not been previously reported in rehabili-
tation research. However, the method is consistent with the 
notion of finding clinically meaningful outcomes in both 
motor impairment (UEFM) and functional activity (AMAT) 
dimensions, and has been used in other contemporary reha-
bilitation studies like the EXCITE trial.6 It should be noted 
that differences among clinical trials in the outcome mea-
sures used to characterize activity and impairment prevents 
direct comparison of results across different trials.50
In addition to selection of the most meaningful outcome 
measures, assessing them at the appropriate intervals pos-
tintervention is also important. In the present study, the pri-
mary endpoint was measured at 4 weeks after completing 
therapy. However in the post hoc secondary analysis, the 
investigational group had sustained improvements at 24 
weeks posttherapy and these effects were not attenuated 
over time. In contrast, a notable decline in motor perfor-
mance was observed in the control group between the 12 
(35% treatment response rate) and 24 week (15% treatment 
response rate) assessments. A similar pattern of group dif-
ferences were also observed in the Adams27 and Baker28 tri-
als, and also in a recent study that used low-frequency 
rTMS to stimulate the contralesional hemisphere of patients 
3 to 9 months poststroke.51 At 1 month postrehabilitation, 
there was no significant difference in the UEFM scores 
between treatment and sham groups. But, at 24 weeks post-
therapy treatment group patients had a clinically significant 
improvement, while the sham group’s performance 
declined.51 The investigational group response rate at 24 
weeks suggests that the EECS intervention induced sus-
tained functional motor improvements, but it could have 
also provoked delayed gains in motor function. Structural 
and functional plasticity resulting from EECS in preclinical 
animal stroke models is observed immediately,14-16 but its 
long-term sustainability has not been studied in detail. The 
positive trend in the investigational group responder rate at 
the 12- and 24-week assessments could be attributed to a 
delayed translation of the EECS-induced structural altera-
tions into gains in motor performance. Neuroprotective, 
neural repair, and neurorestorative mechanisms different 
from the ones responsible for the initial response to neuro-
nal stimulation have been observed in cerebral ischemic 
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animal models52, and can be potentially responsible for the 
long-term consolidation of motor learning seen in the inves-
tigational group. In severely impaired animal stroke mod-
els, EECS failed to significantly enhance the efficacy of 
task-oriented rehabilitation, but movement abnormalities 
were reduced during skilled motor tasks.53 Reduced depen-
dence of the investigational group on compensatory strate-
gies postrehabilitation, and a shift in the control group’s 
movement strategy from optimally restored movements to 
suboptimal compensation-induced motor control54,55 could 
explain the decline of the control group’s performance over 
time.
Finally, the single-blinded design of the present study is 
a notable limitation. For ethical considerations a sham sur-
gery trial was not supported by the FDA, and patients and 
clinicians charged with their care were not blinded to treat-
ment assignment. Determining the safety of a novel device 
is mandatory and supersedes adherence to standards for 
research design. However, after the safety of targeted com-
bined subthreshold CS with rehabilitation has been estab-
lished, a sham-controlled neurosurgical trial may be 
permissible, especially if a late crossover to treatment is 
provided for patients randomized to sham.
Conclusions
The Everest phase III trial was unsuccessful in attaining its 
primary efficacy endpoint at 4 weeks posttreatment. Cortical 
stimulation delivered during task-oriented upper limb reha-
bilitation did not result in significantly higher functional 
motor gains in investigational group patients when com-
pared to the control group patients who underwent only 
rehabilitation. Although secondary post hoc analyses 
showed that investigational group patients exhibited signifi-
cantly better functional improvements 24 weeks postreha-
bilitation, the results should be viewed with caution due to 
the inability to rule out a Hawthorne effect (ie, more atten-
tion from the investigators to the investigational group), and 
also due to the lack of a sham surgery control group. These 
concerns are equally relevant for the small subgroup (n = 13) 
of patients whose stimulators were able to evoke hand 
movements. The Everest trial confirmed a consistent find-
ing that stroke patients with mild to moderate upper extrem-
ity hemiparesis could realize improvements even long after 
the occurrence of an ischemic insult in the brain. Finally, we 
established that the safety profile of cortical stimulation in a 
large-scale multicenter clinical trial is consistent with other 
similar neurostimulation modalities. Future trials with an 
enhanced study design, patient selection, and lead localiza-
tion techniques may be able to overcome the limitations of 
this trial, and may show promise in establishing cortical 
stimulation as an accepted treatment modality during stroke 
rehabilitation.
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